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Abstract 
W01 and W02 are conformation-specific monoclonal IgMs that bind the fibril state of the amyloid 
Af) peptide (1-40), as well as amyloid fibrils of other disease-related proteins. Significantly, the 
antibodies (Abs) do not bind the soluble, monomeric state of Af) (1-40) or the precursor form of 
other amyloids. The Abs have been sequenced and analyzed to study the role of the unique and 
unusual residues in WO1 and W02. Three-dimensional models of the Fv fragments of WO1 and 
W02 were generated with Web Antibody Modeling. A left-handed, six-rung structural model of 
the Af) amyloid core was evaluated by docking it with the Fv models of WO 1 and W02. The 
results predict binding of WO1 and W02 to Af) via hydrogen bonds and ionic pairing between the 
CDRs and the protofilament face consisting of residues 23-27. W01 and W02 bind the model in 
similar configurations; binding to W02 is predicted to rely less on ion pairing. The results support 
the A~ modeL Binding ofW01 experimentally determined to be sensitive to salt and pH 
conditions, suggesting electrostatic interactions are important for binding; this result supports the 




The aggregation of normally soluble proteins into insoluble, unbranched fibrils is the 
underlying pathology of a family of diseases known as the amyloidoses.] The hallmark event in 
amyloidogenesis is a change in the secondary and/or tertiary structure of a normal, soluble protein, 
rendering it prone to self-assembly into highly ordered para-crystalline arrays, or fibrils. More than 
20 proteins have been clinically identified as precursors of amyloid fibrils in vivo. These include 
the anlyloid precursor protein (APP), Islet amyloid polypeptide (lAPP), a-synuclein, transthyretin 
(TTR), immunoglobulin light chain (LC), polyglutamine-repeats, and prion proteins, that are 
associated with diseases such as Alzheimer's,2-4 type II diabetes,5,6 Parkinson's disease,7-9 familial 
polyneuropathy,lO light chain associated (AL) amyloidosis, I 1-13 Huntington's disease,4,14 and the 
spongiform encephalopathies. 15 By understanding the three-dimensional structure of such fibrils, 
we might design novel agents for detection and/or therapeutics. It is notoriously difficult to extract 
structural information directly from amyloid fibrils, which are insoluble and non-crystalline, so a 
great deal of study has gone into fiber diffraction studies,16-18 mutation studies,19 microscopy, 17,20,21 
proteolysis,22,23 ESR,24,25 NMR,24,26 SANS,27 and deuterium exchange28-31 in an ongoing attempt to 
elucidate the molecular structure of the amyloid AP fibrils associated with Alzheimer's disease. 
There is no consensus model for AP structure, but most models incorporate a cross-beta 
secondary structure. The cross-beta structure (in which the fibril axis is perpendicular to the chain 
direction) of AP models is derived from the 4.75 Ameridional reflection in fiber diffraction 
studies. A stacked, parallel beta-sheet arrangement is suggested by Burkoth, Benzinger, and 
others,24,27,32 while a pair of concentric cylinders was proposed by the late M. F. Perutz , et al.33 An 




One recent model of the A~ protofilament features a trigonal prism of stacked, parallel A~(l5-36) 
polypeptides; the model is visible in Figure 5. This model is consistent with hydrogen-deuterium 
exchange, limited proteolysis, solid-state NMR, EPR, and proline-scanning mutagenesis data.38 The 
model remains stable and gains order during molecular dynamics simulations, supporting the 
viability of the trigonal prism model. The proposed fibril model (of 6 proto fil aments ) that 
accompanies the protofilament model appears to be consistent with electron microscopy. Hence, it 
may serve as a starting model for simulating A~-antibody interactions. 
Each unique monoclonal antibody binds specifically to a particular antigen via an antigen 
binding domain of the Ab, the Fab domain, recognizing a specific antigenic region, the epitope. 
They can thus be used to detect and diagnose certain conditions, such as disease or drug use. They 
are also useful as therapeutic agents with precise targeting and correspondingly reduced side 
effects. The monoclonal antibodies WOl and W02 appear to recognize a common conformational 
epitope shared by several different types of amyloid fibrils, with little dependence on amino acid 
39 sequence. The two bind the same antigen with similar affinities for the A~ fibri1.39 This result 
opens the door to targeting whole classes of amyloid fibrils for detection and therapy.4o The 
success of antibody modeling algorithms at predicting crystal structures of antibody variable 
regions41 encouraged us to use computed models ofWOl and W02 Fvs for docking simulations, 
albeit cautiously. 
The program Autodock predicts the interaction of ligands with macromolecular targets. 
Autodock is flexible enough to accept the hexamer protofilament model as an input. Since WO 1 
and W02 bind to A~ amyloid, we hypothesized that a model of the A~ protofilament would, if 
correct, dock predictably to a model of the variable regions of WO 1 and W02. Here is presented 
the configuration predicted by Autodock3 for the binding of the Fvs of antibodies WOl and W02 
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to a model of AP protofilament. Also are comparisons of the sequences of WO 1 and W02 variable 
regions to each other and to sequences in the database and experimental data that supports the 
predicted model ofW01-AP binding with respect to salt-dependence. 
Methods 
Sequence analysis- The nucleotide sequences of WO 1 and W02 were obtained by 
cloning and confirmed by multiple cloning using high fidelity polymerases, and further confirmed 
by extended N-terminal amino acid sequence from analysis of the protein.42 Initial alignments were 
performed using Molecular Operating Environment (MOETM43), with Ab sequences obtained from 
the Protein Data Bank44,45. An extensive alignment was done using the Kabat sequence database 
testing program46. BLASTP analysis47 was run on the W01 and W02 variable light chains using 
the Non-Redundant Protein Database at the San Diego Supercomputer Center. Canonical classes 
are based on Chothia nomenclature48 and numbering scheme is that of Kabat49. 
Electrostatic Analysis - Electrostatic surfaces were calculated using DelPhi, a part of the 
InsightII® graphical software package. Models were displayed and manipulated with InsightII® 
and all computational work done on a Silicon Graphics computer system. 
Model Generation- Models ofW01 and W02 variable regions (Fv) were generated using 
the Web Antibody Modeling algorithm, W AM.41 W AM is an improvement on the AbM program 
50-53 with greater capability in modeling the highly variable H3 loop through a combination of 
knowledge-based and ab initio methods41 . The WAM algorithm has a record of producing models 
that are 1.0-2.8 A RMSD from observed structures for the (notoriously low homology) heavy chain 
CDR3, and better than that for the canonical loops (typically 1.0-2.5 A RMSD). 
Docking - preparation. With Anna Gardberg in the Dealwis lab, docking simulations were 
performed using Autodock and a Silicon Graphics workstation. Control calculations performed 
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with a protein-peptide complex and a protein-ligand complex of known structure showed that the 
charges assigned from forcefield calculations performed by AutoDockTools yielded less accurate 
results than those assigned by AMBER forcefield calculations54,55 performed by InsightII.56 We 
report here the procedure that we used to assign such charges. A PDB file of the Ap 1-40 
hexameric protofilament model after molecular dynamics simulations ("AP6 model", which models 
residues Gln15 through Va136)38 was kindly provided by Juntao Guo and Ying Xu. The atom 
names were standardized and hydrogen atoms added in riding positions via Refmac5.57,58 After 
capping the termini of each chain with neutral end groups, the InsightII program calculated partial 
charges for each atom (including H's) in the AP6 model via the AMBER force field. Calculating 
the summed formal and partial charges for the AP6 model verified that the model is electrically 
neutral. 
Docking - computation. Autodock-style PDBQ files were prepared files with mol2topdbq 
and mol2topdbqs, awk-based utilities packaged with Autodock3.59 For purposes of solvation 
calculation, we designated the Fab models the proteins and the AP6 model the ligand. Despite the 
thermodynamic importance of side-chain motion,60 neither the Fvs nor the AP6 model were 
permitted any torsional freedom; the Autodock package does not permit the side chains of the 
protein to move, and the Autotors utility for designating rotatable bonds in the ligand allows a 
maximum of 32, not nearly sufficient for a "ligand" the size of the AP6 model, which contains 
2040 atoms. Grid parameter files were generated via mkgpj3 (a script which comes packaged with 
Autodock3) and adjusted to compensate for the large volume required for the interaction of the 
Fab's complementarity determining region (CDR) with the AP6 model. The npts parameter, which 
controls the number of points in the docking grid, was adjusted to "120 120 120", the spacing 
between points was increased to 0.55 A, and the center of the computational volume was moved. 
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The final gridded regions encompassed the CDR of the Fv (as well as all of the heavy chain and 
most of the light chain of the model for WOl, and all save the C-termini for W02) and the starting 
position of the A~6 model, with room for rotation and translation. Grid generation was performed 
with Autogrid3. 
Docking parameter files were prepared with mkdpj3 and adjusted by hand. The qstep 
parameter was changed to 180 for more initial rotational freedom. The initial gayap_size of 10 
was insufficient for meaningful clustering results, so that parameter was changed to 50. 
Contact analysis. Contacts between the Fv models and the A~6 model in the predicted 
docking complexes were analyzed with Tadeusz Skarzynski's program CONTACT. 58 Docking 
clusters and configurations were examined in Pymol,61 with residue charge surfaces visualized. 
Electrostatic surface plots for publication were generated by the DelPhi module of InsightII. 56 
Angles between solutions were computed by calculating the average direction vector along the 
protofilament axis for each solution and taking the inverse cosine of the dot-product of direction 
vectors. 
Salt Effects on Binding WO1. Binding of the WO 1 antibody to A~ fibrils was tested under 
various salt and pH conditions, experiments conducted by Israel Huff and data communicated. A 
buffer concentration of5mM was used throughout: HEPES at pH 7.5 with 1) no salt, 2) 150 luM 
NaCI, 3) 600 mM NaCI, 4) 150 mM KCI, and 5) 75 mM Na2HP04 comprised the salt-effects 
experiments; 150 mM NaCI with 6) citric acid pH 3.0, 7) citric acid pH 5.8, 8) PIPES at pH 5.8, 9) 
PIPES at pH 7.4, 10) Bicine at pH 7.4, 11) Bicine at pH 8.5, 12) CHES at pH 8.5, and 13) CHES at 
pH 10.0 comprised the pH-effects experiments. 
All buffer compounds except citric acid were ordered from Calbiochem. HEPES has low 
ionic strength, so it should not interfere greatly with comparing the different salts. N a2HP04 has 
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roughly double the ionic strength of the other 2 salts so it was used at half the concentration for a 
balanced comparison. The salt-effects experiments were buffered to pH 7.5, near physiological pH 
conditions. The pH effect experiments contained 150 mM NaCI to provide approximate 
physiological ionic strength conditions. Four different salts were tested at comparable ionic 
strengths to determine if the particular salt present in the buffer has a significant impact on antibody 
binding. The four chosen were lxPBS, NaCI, KCI, and NaP04• lxPBS is the standard buffer used 
in the binding experiments. The other three salts were chosen to compare two different anions and 
cations. 
RESULTS 
Sequence analysis. Comparison ofWOl to W02. The WOl and W02 Fv residue sequences 
were initially compared to one another, then compared with sequences fronl the Kabat database to 
search for anomalies, unique features, or homologies to other antibodies. An alignment of the 
CDRs is shown in Figure 1. The light chain variable regions share 66% identity (800/0 similarity) 
and the heavy chain variable regions share 820/0 identity (85% similarity). While both sequences are 
rich in hydrogen bonding residues, WO 1 V L has a greater proportion of Asn and GIn residues 
(10.70/0 WOl vs. 4.90/0 W02) and of (charged) Asp, Glu, Arg, and Lys residues (13.3% vs. 11.5%), 
while the W02light chain is richer in Ser residues (13.2% for WOl VL, 20.3% for W02 VL). Of 
the eleven additional serine residues in W02's light chain variable region, nine are in the CDRs; 
their counterparts in WOl are Gly, Asn (3), His, a deletion, Lys, Asp, and Thr. The number of 
positively and negatively charged residues in the V L region is similar; the number of charged 
residues in the V H is identical. The WO 1 and W02 heavy chain variable regions are more similar in 
overall sequence, but W02 is richer in serine residues (W01: 12.8%, W02: 14.9%). Only one of 
the additional serine residues is at a CDR, and it replaces a (similar) threonine residue. 
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Overall charge composition of the Fv fragments is very similar, with isoelectric points (pIs) 
of the variable regions calculated to be: WOI VH 7.3, VL 8.7, W02 VH 7.2, and VL 8.7. The CDRs 
of the light and heavy chains are rich in hydrogen-bonding residues relative to anti-lysozyme and 
gerrnline antibodies, suggesting that hydrogen bonding plays a role in amyloid-recognition. The 
compositions of CDR I and CDR2 feature a much higher composition of hydroxyl residues in W02 
than in WOI. This disproportion could feature in any antigen binding differences or trends 
between the two Abs. CDR3 of the heavy chain shows high variability, so comparisons are 
difficult, but the three-charge region R98, D99, DIDO in WOI heavy-chain CDR3 is striking, this 
being the only chain with three-charge region. (W02 has RRL here). Figure 1 displays the sequence 
comparison for the CD Rs. 
a) 
VL CDR1 24 25 26 27 28 29 30 31 31a 32 33 34 
W01 R A S G N I B N Y L A 
W02 T A S S S V S S S Y L B 
O:'-Lyso R A S Q N I S,B N N L B,A 
Germ. R,K S,A S Q S,N I nh* nh S nh L nh 
Kappa R,K A,T S Q nh V,I nh S,T nh L nh 
CDR2,3 50 51 52 53 54 55 56 89 90 91 92 93 94 95 96 97 
W01 N A K T L A D Q B F W S T P Y T 
W02 S T S N L A S L Q Y B R S P Y T 
O:'-Lyso Y T T,S Q,T S,L nh D,S Q Q F,Y nh S P R,L T 
Germ nh A,V S,A nh R,L D,E S nh Q nh S nh nh P R T 
Kappa nh A S nh R,L nh S Q Q S,Y nh S,D nh P R,L T 
b) 
VB CDR1 26 27 28 29 30 31 32 33 34 35 
W01 G Y T F T E Y T M B 
W02 G Y S F T G Y T M N 
O:'-Lyso G Y T,S F T T Y W I,V E,S 
Germ G F T F T D Y Y M S,B 
Kappa G F,Y T F T D Y Y I,M B,K 
CDR2 50 51 52 53 54 55 56 57 58 
W01 G I N P N N G T S 
W02 L I N P Y N G T S 
O:'-Lys E I L P G S nh T Y,D 
Germ F I R nh nh nh nh T E,K 
Kappa nh I nh P nh nh G,S T nh 
Figure 1: 
CDR composition of a) V LS and b) V HS compared with those of anti-lysozyme, germ line, and kappa-light-chain 
antibodies. CDR3 for VH not shown as this region has high variability. *nh signifies no homoJogy 
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Light Chain. A preliminary sequence alignment was performed using a database of various 
antibody sequences, including subsets of anti-lysozyme Ab chains and germline Ab chains. The 
results showed a high degree of homology between the chains on the whole, with several residues 
noted as distinctive. (Table I). In WOl 's light chain CDRs, there are charged residues occupy 
positions occupied by hydroxyl residues in W02 and the comparison sequences: Arg24, Lys52, and 
Asp56. Similarly, theW02-unique charged residue Arg93 replaces a hydroxyl residue in WOl and 
the other comparison sequences. In other words, the unique residues of WO 1 are not conserved in 




Equivalents Residue exhibited by chains with non-identity 
Lys42 Ser43 No None charged, only Gly, GIn, Tyr 
Lys52 Ser53 Lys only in W01 No charged, 95% Tyr or Ser 
Asp56 Ser57 Asp in W01 and (AL) 990/0 Pro, (G) have Thr/Ser 
Lys74 Thr75 Lys only inWO] 100% GluiAsp, (G) has Thr 
Table I: Light chain-unique residues and comparison for W01 residues that are less than 10% homologous in the 
initial alignment tests. The alignment was done with specific interest in the anti-lysozyme Abs as well as germline 
Abs, and any residues here are noted if appearing in either chain. The residue is listed with its location, as well as the 
residues that were most commonly shared throughout the other Ab sequences. The equivalent residue from W02 is 
also included for comparison. Codes: antilysozyme (AL), germline (G). 
Light Chain Kabat Alignment. A more extensive alignment was done using the Kabat 
sequence database testing program. The WO 1 V H and V L sequences were compared to the database 
of 2707 light chains and 3471 heavy chains. The chain of interest was displayed against a code of 
typical residues by name or property, indicating what residue or what type (hydrophobic, acidic, 
basic, hydroxyl, etc.) of residue occurs at each position in the majority of the comparison 
sequences. The unique (defined as: occurring in less than 1 % of the chains at a certain position) 
residues Lys42 and Lys74 had no consensus within the database. Lys52, however, was a hydroxyl 
residue in the majority of the 2701 chains. None of the W02-unique charged or hydroxyl residues 
showed any incongruity. 
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Heavy Chain. Through the preliminary alignment including the anti-lysozyme, germline, 





Equivalents Residue exhibited by chains with non-identity 
Lys63 Lys63 WOIlW02, (G) No other charged residues 
Lys65 Lys65 WOI/W02, (G), (AL) 100% Val, Leu, or Phe 
Lys67 Lys67 WOIlW02, (G), (AL) 100% Gly, Ser, Asp 
Asp73 Asp73 WOIlW02, (G), (AL) Mostly Asp/Glu 
Lys74 Lys74 WOIlW02, (G) 99% Asp/Glu 
Arg84 Leu84 Arg only in WO] Non-consensus, but no other charged 
Table II: Heavy chain unique residues and comparison. The residues displaying less than] 0% homology in 
the initial alignment tests are included here. Any germline or anti-lysozyme Ab commonalities are noted, as well as the 
residues displayed in the chains which are not homologous to the WOI/W02 heavy chains. Codes: anti lysozyme (AL), 
germline (G). 
Similar to the light chain results, the most striking disparities between WOllW02 and comparison 
sequences occur with charged residues, here Lys63, Lys65, Lys67, Lys74, Asp73 (both WOl and 
W02) and Arg84 (WOl only). 
Kabat Alignment. Again, the Kabat alignment was performed to determine uniqueness or 
find other distinct residues. None of the above charged residues were found unique, and the typical 
equivalent had no consensus. The only significant discrepancy was the Asn44 of the W02 heavy 
chain. The Asn residue found at this site is found in only 13 examples, 0.326% of the database. 
Typically, a Ser residue is at this position. 
Electrostatic surface potentials for WOl and W02. WOl and W02 Fvs display regions of 
significant charge density, indicated in the electrostatic potential map in Figure 2. Though the pIs of 
the WOl and W02 Fvs are nearly neutral, they clearly have highly charged regions. The presence 
and distribution of these charged segments indicates a possible role of charge interactions in 
antigen binding. The line of positively charged residues on each of the light-chains suggests a 
template for hydrogen bonding and salt bridges. 
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Figure 2. Electrostatic surfaces for WO 1 (left) and W02 (right) Fv models. The viewer faces the CDRs. In each image, 
the heavy chain fragment is on the left. 
Fv Models. Ofthe W01light chain's unique lysine residues (42, 52, and 74), only Lys52 is 
at the CDR and plays a role in docking. Lys74 and Lys42 are on the framework; Lys42 sits near the 
heavy-light interface. The heavy chain's unique residues (common to W01 and W02), Lys63 , 
Lys65, Lys67, Asp73 , and Lys74, likewise do not occupy the CDR, and play no part in the binding 
predicted by these models. W01light-chain Asp56 (unique to W01 and anti-lysozyme Abs) does 
playa role, however. 
Electrostatic Surface Potentials for AfJ6. The most striking features of the A~6 model are 
the bands of charged residues aligned along the stacking axis, shown in Figure 3. These charged 
bands are a consequence of the in-register parallel-stacking of the model. Labeling the 
protofilament face containing residues 17-22 "A", 23-27 "B", and 28-36 "C" (A~ 1-40 numbering 
basis), we see that faces A and C display exposed hydrophobic residues. 
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Figure 3. Electrostatic surfaces for the A, B, and C faces of the AP6 protofilament model. The line ofGlu22 and Asp23 
residues (shown in red) at the corner ofthe A and B faces is particularly striking. 
Proto filament Packing model. Figure 4 shows a more detailed three-dimensional view of the 
6-protofilament packing model suggested by Guo, Wetzel, and Xu.38 Each unique protofilament 
face is exposed twice on the outside of the fibril. 
Figure 4. A more detailed (but still schematic) three-dimensional view of the 6-protofilament packing model suggested 
by Guo, Wetzel, and XU.38 Each unique protofilament face is exposed twice on the outside of the fibril. Color scheme: 
A-face, blue; B-face, red; C-face, green. 
Docking. WOI-AfJ6. AutoDock3 predicted 50 binding configurations for W01- A~6. Both Fvs 
were treated as rigid bodies. For W01- A~6, Autodock3 found 41 distinct conformational clusters 
(using an RMSD-tolerance of 1.0 A), of which 8 contained more than one member. The variation in 
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energy from the best to the worst solution was 7.0 kcal/mol. Although there was one cluster of two 
solutions in the top 7, more intriguing is a collection of related clusters beginning at the 8th-ranked 
solution. In total, 21 solutions have the B face of the A~6 protofilament model at the light-chain 
CDR, with some overlap onto heavy chain CDR. Some are offset by one, two, or three monomers 
(i.e. , the stack of six A~ monomers is shifted along the stacking axis), others by angles less than 
27°. This is the largest supercluster. The particular solution used for the following analysis was the 
lowest-energy member of this supercluster, which is 3.5 kcal/molless favorable than the lowest-
energy solution. 
Figure 5. a. WO 1 and b. W02 Fv docked with A~6 protofilament model in the predicted configuration. The heavy 
chain is on the left, the light chain is on the right, and the CDRs are highlighted. The A~6 model is shown colored 
according to residue: negative, red; positive, blue; polar, pink; hydrophobic, black. c. The two solutions are showed 
overlain. 
Salt Bridges and Ion Pairs. This docking model indicates that the line of Glu22 and Asp23 
residues in the A~6 model binds to the corresponding line of polar and positively charged residues 
ofW01's light-chain CDR through salt bridges and hydrogen bonds. The line of Lys28 residues 
likewise interact with the trail of polar and negatively charged residues of the light and heavy chain 
CDRs. Breaking the pairs down by Szilyagi and Zavodsky classification, there are four bonds at < 
4.0 A, six bonds between 4.0 and 6.0 A, and ten pairs between 6.0 and 8.0 A. 
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Hydrogen Bonding. The 0 and N atoms of the side chains of the line of Asn27 residues on 
the A~6 model make hydrogen bonds with Tyr and Asp residues of WO 1. The carbonyl 0 atoms of 
the line of (inward-pointing) Val24 and Gly25 residues bond to Tyr residues ofWOl. The 
backbone N of inward-pointing Ser26 makes some possible hydrogen-bonds. There are 17 likely H­
bonds at less than 3.5 A(two ofwhich were also counted as close ion pairs), and 56 possible H­
bonds between 3.5 and 5.0 A (five of which were counted as close or mid-range ion pairs). There is 
some overlap with the salt bridges listed above. 
Hydrophobic Interactions. There are no aromatic rings on the B-face of the A~6 model, and 
the hydrophobic Val24 side chain points toward the interior of the A~6 model, so hydrophobic 
interactions between WOl and the A~6 model are not observed in this docking model. 
Docking. W02-AjJ6. AutoDock3 predicted 50 binding configurations for W02- A~6. Both Abs 
were treated as rigid bodies. For WO 1- A~6, Autodock3 found 42 distinct conformational clusters 
(using an RMSD-tolerance of 1.0 A), of which 5 contained more than one member. The variation in 
energy from the best to the worst solution was 9.3 kcal/mol. There was one cluster of two solutions 
in the top 13, but the largest cluster began with the 14th-ranked solution. Within 1.0 A R.M.S.D., 
there are 5 similar solutions. In total, 11 solutions have the B face of the A~6 protofilament model 
at the light-chain CDR, with slight overlap onto heavy chain CDR. One of them is offset by one 
monomer, others by acute angles. This is the largest supercluster. This solution resembles the 
160supercluster solution found in the WO 1 docking, but makes a ~ angle to it. The particular 
solution used for the following analysis was the lowest-energy menlber of this supercluster, which 
is 6.4 kcal/molless favorable than the lowest-energy solution. 
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Salt Bridges and Ion Pairs. The analysis for this docked conformation is very similar to that 
of the WOI-AP6 solution, but there are no salt bridges at less than 4.0 A, only two ion pairs 
between 4.0 and 6.0 A, and five between 6.0 and 8.0 A. 
Hydrogen Bonding. Thirteen likely hydrogen-bonds at less that 3.5 A and 66 possible 
hydrogen-bonds between 3.5 and 5.0 A exist between W02's Fv model and the docked A~6 model. 
Hydrophobic Interactions. No hydrophobic interactions were observed for this docking 
model. 
Binding vs. Salt Concentration. Binding was tested under three different ionic strength 
conditions: 0 mM NaCI, 150 mM NaCI, and 600 mM NaCI (Table 1). Binding was strongest in the 
near physiological ionic strength buffer, 150 mM NaCI, at an affinity of 4 nM (Figure 6). In a low 
ionic strength buffer, 5 mM HEPES only, binding is similar. In a high ionic strength buffer, 600 
mM NaCI, binding dropped sharply. This nlanifested in a reduction of both the magnitude and the 
affinity of binding. 5 mM HEPES only: 4 nM; 150 mM NaCI: 4 nM; 150 mM KCI: 8 nM; 75 mM 
NaP04 : 10 nM; 600 mM NaCI: 20 nM; and lxPBS: 2 nM. The significantly reduced binding in 
high salt suggests that electrostatic interactions are relatively important to binding and hydrophobic 
interactions are relatively unimportant. 
16 

Salt Effects on WOi Binding 
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Figure 6. Salt effect on WOl binding. Binding under various salt conditions was calculated from sigmoid midpoints: 
5 mM HEPES only was 4 nM, 150 mM NaCl was 4 nM, 150 mM KCl was 8 nM, 75 mM NaP04 was 10 nM, 600 mM 
NaCI was 20 nM, and 1 xPBS was 2 nM. 
W01 binding was tested in a range of pH conditions. Citrate pH 3.0 showed essentially no 
binding, citrate pH 5.8 shows 2 nM binding, PIPES pH 5.8 was> 20 nM, PIPES pH 7.4 was 2 nM, 
Bicine pH 7.4 was 1.5 nM, Bicine pH 8.5 was 16 nM, CHES pH 8.5 was 10 nM, pH 10.0> 50 
nM). The data produced a continuum of binding affinities with the strongest binding at near 
physiological conditions, pH 7.4 (Figure 7). There was, however, a discontinuity at pH 5.8 
between the PIPES and citrate buffers. Even with the gap present, a clear trend arose with binding 
dropping off sharply at higher and lower pH conditions. This indicates that W01 is pH-optimized 
for AP amyloid binding. If hydrophobic interactions were predominant in binding, this would 
likely not be the case. This reinforces the salt effect results suggesting that binding depends at least 
in part on electrostatic interactions. 
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Figure 7. pH effect on WOl binding. The show binding under various pH conditions. Binding affinities were 
calculated from the sigmoid midpoints: citrate pH 3.0 showed essentially no binding, pH 5.8 was 2 nM, PIPES pH 5.8 
was more than 20 nM, pH 7.4 was 2 nM, Bicine pH 7.4 was 1.5 nM, pH 8.5 was 16 nM, CHES pH 8.5 was 10 nM, pH 
10.0 was very low binding (could not be calculated, but no better than 50 nM). 
DISCUSSION 
Comparison with experimental results. The model of WO1- A~6 docking that we have 
proposed, featuring many H-bonding pairs and salt-bridges, is in agreement with salt-dependence 
binding studies. It suggests that the positive-negative pattern on the "B" face of the A~6 model of 
the amyloid A~ protofilament offers a good recognition template for antibodies. The docking 
model shown in Figure 5(a) is in agreement with the experimental data available on salt effects in 
WOl A~ binding. The bonding ofW02 to the A~6 model has no strong salt bridges, which 
suggests that salt-effects for W02 and A~ will be less than those for WOl and A~, and that 
hydrogen bonds are of paramount importance for W02-A~ binding. 
Assemblies. Strictly speaking, the Fv models presented here are docked only to a 
protofilament, but these docked models are consistent with the hierarchical fibril model for A0 
amyloid proposed by Guo, Wetzel, and Ying. Their model consists of six A06 prisms, packed 
vertically against one another in two rows of three. Our rendering of this model, shown in figure 4, 
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shows that each protofilament face is exposed twice on the outside surface of the fibril model. The 
AP6 model likewise models a single antigen-recognition region for WO lIW02, whereas the 
physiological IgM presents ten recognition sites, resulting in high avidity and increased total 
binding strength. 
Implications. The in-register parallel beta-stacking of the AP6 model requires that each 
residue of the polypeptide line up with its equivalent in the next layer of the prism. Thus, while 
Glu22 is makes peptide bonds to Ala21 and Asp23 , it makes hydrogen bonds to Glu22 on 
neighboring strands. Viewing a face of the prism, then, one would see lines of equivalent residues. 
The line of Glu22 and Asp23 residues (Figure 3) is predicted to bind to the corresponding line of 
positive and polar residues ofW01 's light-chain CDR. The line of Asn27 and Lys28 residues 
likewise interact with the trail of negative and polar residues. 
The lineup of positive and negative charges on the B face with those at the CDR suggests 
another available binding mode. The A face of the AP6 model also has such a lineup of charges 
(Figure 3). The N -terminal residues of the AP6 model occlude part of the A face in this model, 
which was not allowed torsional freedom, so the A face was less accessible for binding than the B 
face. Even so, 2/50 unclustered solutions for W01 and 5150 for W02 (out of fifty) did predict some 
form of docking to the A face. It is worth noting, furthermore, that earlier simulations with an un­
minimized AP6 model (in which the N terminal residues took other orientations) yielded a 
supercluster of docking solutions at the A face of the AP6 model with W01. It is thus likely that a 
more computationally intensive docking simulation, one which allowed rotation around the bonds 
of the AP6 model, would have shown a bimodal distribution of solutions, one at the A face and 




The C face of the AP6 model present mostly hydrophobic residues and positively charged 
residues and would seem to be a poor fit for the WOI and W02 CDRs. Nonetheless, 8/50 
unclustered solutions for WOI and 9/50 for WOI predicted some form of binding to the C face. 
While these solutions are unrelated and unclustered, they may have some relevance, so binding AP 
to the C face cannot be ruled out. 
Conclusions. 
The sequences of two amyloid-recognizing IgMs were compared and analyzed. Structural 
models of their Fvs were created. WO 1 's Fv was found to be unusually rich in charged residues, 
while W02 is rich in Ser residues. Conditions for simulating the docking of AP amyloid 
protofilament to these Fvs were reported. Autodock3 predicted binding between the protofilament 
face consisting of residues 23-27 ("B") and the CDRs of the antibodies. The results for WO 1 agree 
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IgM Structure and Optimized WOl-W02 Protelolytic Cleavage 

An IgM is a pentameric antibody molecule, with each of the five subunits having IgG-like 
structure, with two Fab antigen binding sites. A joining, or "J" chain connects the five J.l heavy 
chains. A schematic of this pentameric arrangement is shown below: 
JeHAI 
Due to the large size of the IgM (nearly 900kDa), crystallization of the intact Ab is extremely 
difficult and an IgM structure has not been solved. Thus, efforts have been made to enzymatically 
fragment the IgM into smaller, more crystallizable protein pieces. Considering the aim of the WO 1­
W02 project is to further elucidate amyloid structure, crystallization of the amyloid fibril binding 
Fab fragment is an obvious goal, with the structure of the CDR regions showing motifs for antigen 
recognition as well as confirming the docking models. In order to achieve this, a cleavage protocol 

















Papain cleaves in the hinge region, just above the two disulfide bonds, resulting in two Fab 
domains from every IgG. In the case ofW01 and W02, ten Fab' s would be cleaved from the IgM 
monomer, purified and crystallized. Each IgM is obviously different, so a cleavage protocol should 
be tailored to the Ab through optimization. Our optimization involved varying pH, papain:Ab ratio, 
and time, with the procedure as follows: 
1. 	 Purify WO 1 or W02 from hybridoma culture through size exclusion chromatography 
2. 	 Preactivation of papain in 50mM NaCI, 50mM NaP04, 10mM cysteine, 2mM EDTA, pH 
6,6.5 ,7 30 minutes at 37°C. 
3. 	 Add papain at 1 :40 and 1:8 (five fold change) ratios 

4. 	 Incubate at 37°C for 12 hours, taking timepoint samples at 30min, 1h, 2h, 4h, 8h, 12h. 

5. 	 Run SDS-PAGE gel electrophoresis with Coomassie or silver staining to analyze cleavage 

6. Select best conditions, repeat experiment full scale 

7.. Purify Fab through affinity or size exclusion chromatography, crystallize. 

Our results showed that the pH 7.0, 4hr, 2.5% papain condition shows adequate cleavage with 
relatively little non-specific cleavage side products. This can be seen on the silver stained SDS 




Problems in purification stem from the fact that the Fc regions of the IgM might be cleaved from 
the J chain, leaving both the Fc and Fab chains at nearly the same molecular weight (~50kDa). 
Thus size exclusion chromatography may not be efficient, and affinity resins such as Protein L or 
Protein A columns that bind Fc domains can be employed to purify the Fab. 
An image of very small crystals is shown here: 
Once these can be optimized, grown to sufficient size, and found to diffract X-rays, a structure of 
the Fab domains of WO 1 and W02 could be found. This work is ongoing, and a solved structure 





WAM generated model images 

For reference, several of the WAM generated WOl and W02 models rendered using InsightII on a 
Silicon Graphics Octane ™ workstation are shown below: 
This is a ribbon view of the model of W02, with heavy chain on left and light chain on the right. 
CDRs are marked by the colored regions: 
pink: Heavy Chain CDR2 orange: Light Chain CDR2 
green: Heavy Chain CDRl purple: Light Chain CDRl 
red: Heavy Chain CDR3 white: Light Chain CDR3 
Below is a ribbon view of the superimposition of the two models, with similar orientation to the 








Electrostatic Surface Images 

More detailed images of the DelPhi generated electrostatic surfaces are shown below, viewer 
looking into the CDRs with heavy chain on left and light on right. 
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